Ticker

Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the

Metagenomi Announces Publication in Nature Structural & Molecular Biology Highlighting Proprietary Compact CRISPR Nuclease with Enhanced Editing Efficiency

Shareholders are urged to contact the firm immediately at no cost or obligation, as there may be limited time to enforce your rights. We would handle the matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

Metagenomi (NASDAQ: MGX - Get Free Report) is expected to be issuing its Q4 2025 results before the market opens on Wednesday, April 1st. Analysts expect the company to announce earnings of ($0.6059) per share and revenue of $7.3270 million for the quarter. Investors are encouraged to explore the company's upcoming Q4 2025 earning overview page

Shares of Metagenomi, Inc. (NASDAQ: MGX - Get Free Report) have been given a consensus rating of "Moderate Buy" by the five brokerages that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, three have issued a buy rating and one has assigned a strong buy rating